omniture

Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2010 Unaudited Financial Results on Tuesday, March 8, 2011

2011-02-24 19:49 1159

NANJING, China, Feb. 24, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2010 on Tuesday, March 8, 2011, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Tuesday, March 8 at 9 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:

 

 

United States toll-free:

 

+1.866.831.5605

 

 

International:

 

+1.617.213.8851

 

 

China Telecom:

 

10.800.130.0399 / 10.800.120.2655 / 10.800.152.1490

 

 

China Netcom:

 

10.800.852.1490 / 10.800.712.2655

 

 

China 400 (for mobile users)

 

400.881.1630 / 400.881.1629

 

 

Hong Kong:

 

+852.3002.1672

 

 

 

 


Please ask to be connected to Q4 2010 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 56440566

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free:

 

+1.888.286.8010  

 

 

International:

 

+1.617.801.6888

 

 

 

 


The passcode for replay participants is: 22405893.The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:
Email: ir@simcere.com


 

 

In Nanjing:
Yehong Zhang
President
Simcere Pharmaceutical Group
Tel: 86-25-8556-6666 ext 8811


 

In the United States:
Kate Tellier
Brunswick Group
Tel: 1-212-333-3810


 

 

In Beijing:
Ruirui Jiang
Brunswick Group
Tel: 86-10-5960-8600


 

In Hong Kong:
Joseph Lo Chi-Lun
Brunswick Group
Tel: 852-3512-5000


 

 

 

 


Source: Simcere Pharmaceutical Group
Related Stocks:
NYSE:SCR
collection